Vimian Group AB (publ) (VIMIAN.ST)
SEK 42.2
(2.93%)
SEK 42.2
(2.93%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 41.27 Million EUR | 4.85% |
| 2022 | 39.36 Million EUR | 82.25% |
| 2021 | 21.59 Million EUR | -71.13% |
| 2020 | 74.8 Million EUR | 5822.57% |
| 2019 | 1.26 Million EUR | 217.71% |
| 2018 | -1.07 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 13.36 Million EUR | 395.26% |
| 2024 Q2 | 13.22 Million EUR | -1.07% |
| 2024 Q3 | 10.09 Million EUR | -23.7% |
| 2023 Q4 | 2.69 Million EUR | -72.77% |
| 2023 Q2 | 10.13 Million EUR | -45.28% |
| 2023 Q3 | 9.91 Million EUR | -2.21% |
| 2023 Q1 | 18.52 Million EUR | 6.92% |
| 2023 FY | 41.27 Million EUR | 4.85% |
| 2022 Q4 | 17.32 Million EUR | 96.3% |
| 2022 FY | 39.36 Million EUR | 82.25% |
| 2022 Q3 | 8.82 Million EUR | 11.26% |
| 2022 Q2 | 7.93 Million EUR | -28.88% |
| 2022 Q1 | 11.15 Million EUR | 175.2% |
| 2021 Q2 | 1.64 Million EUR | -85.59% |
| 2021 FY | 21.59 Million EUR | -71.13% |
| 2021 Q4 | 4.05 Million EUR | -9.27% |
| 2021 Q3 | 4.46 Million EUR | 171.06% |
| 2021 Q1 | 11.43 Million EUR | -14.18% |
| 2020 Q1 | 476 Thousand EUR | 0.0% |
| 2020 Q3 | 3.22 Million EUR | 304.18% |
| 2020 Q2 | -1.57 Million EUR | -431.72% |
| 2020 Q4 | 13.32 Million EUR | 313.28% |
| 2020 FY | 74.8 Million EUR | 5822.57% |
| 2019 FY | 1.26 Million EUR | 217.71% |
| 2018 FY | -1.07 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AroCell AB (publ) | -59.78 Million SEK | 169.034% |
| Devyser Diagnostics AB (publ) | -56.5 Million SEK | 173.046% |
| Immunovia AB (publ) | -296.46 Million SEK | 113.921% |
| Prostatype Genomics AB (publ) | -39.3 Million SEK | 204.999% |
| SenzaGen AB | -14.74 Million SEK | 379.993% |
| Spermosens AB | -10.89 Million SEK | 478.842% |